

Exploring the path to selective TRK inhibition

At Loxo Oncology, our mission is to translate scientific knowledge about the drivers of cancer into selective drugs that deliver rapid benefits to patients

Research suggests that some patients develop cancer because of a gene abnormality involving a protein known as tropomyosin receptor kinase (TRK). Larotrectinib (LOXO-101) is an investigational medicine designed to selectively target TRK fusions. Clinical efficacy and safety is currently being investigated for pediatric and adult patients whose tumors harbor a TRK fusion.

Larotrectinib was developed in partnership with Array BioPharma. FDA has granted larotrectinib breakthrough therapy designation.

The following larotrectinib clinical trials are actively recruiting:

NAVIGATE

NCT02576431 | Study of Larotrectinib in Subjects With NTRK Fusion Positive Solid Tumors

Global, multicenter, single-arm, open-label, Phase 2 basket trial in patients with solid tumors with a fusion of NTRK1, NTRK2, or NTRK3. Loxo Oncology collaborates with the clinical, laboratory, and molecular pathology communities in both academia and industry to help ensure that patients with TRK fusions and their treating physicians are notified about the larotrectinib Phase 2 clinical trial to help integrate a trial recruitment mechanism for appropriate patients into routine clinical practice.

SCOUT

NCT02637687 | Oral TRK Inhibitor Larotrectinib for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors

This Phase 1/2 clinical trial is a multicenter, open-label trial in pediatric patients with advanced solid or primary central nervous system tumors. The trial uses a liquid formulation of larotrectinib, with dose adjusted by body surface area.

Physicians and patients interested in participating in a clinical trial can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 (1-855-687-5123) or send an email to info@loxooncology.com for more information.

The information provided on LoxoOncologyTrials.com is intended only for healthcare professionals. If you are a patient, please consult with your physician.

For additional information about larotrectinib clinical trials, and to view trial site locations, visit clinicaltrials.gov.

Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology's Policy for Access to Investigational Agents describes the principles and government regulations that the company will follow when considering a request. A copy of this policy can be found by visiting loxooncology.com/patients-caregivers.